These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. CRISPR/Cas9 System and its Research Progress in Gene Therapy. Liu W; Yang C; Liu Y; Jiang G Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477 [TBL] [Abstract][Full Text] [Related]
27. Recent Advances in Therapeutic Genome Editing in China. Yang Y; Wang Q; Li Q; Men K; He Z; Deng H; Ji W; Wei Y Hum Gene Ther; 2018 Feb; 29(2):136-145. PubMed ID: 29446996 [TBL] [Abstract][Full Text] [Related]
28. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics. Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365 [TBL] [Abstract][Full Text] [Related]
29. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System. Bellizzi A; Ahye N; Jalagadugula G; Wollebo HS J Neuroimmune Pharmacol; 2019 Dec; 14(4):578-594. PubMed ID: 31512166 [TBL] [Abstract][Full Text] [Related]
30. Huntington disease: Selective deactivation of Huntington disease mutant allele by CRISPR-Cas9 gene editing. Malkki H Nat Rev Neurol; 2016 Nov; 12(11):614-615. PubMed ID: 27686048 [No Abstract] [Full Text] [Related]
31. Gene editing using CRISPR-Cas9 for the treatment of lung cancer. Castillo A Colomb Med (Cali); 2016 Dec; 47(4):178-180. PubMed ID: 28293040 [No Abstract] [Full Text] [Related]
32. Writing the Story of Gene Editing and CRISPR: An Interview with Kevin Davies, PhD. Flotte TR Hum Gene Ther; 2020 Dec; 31(23-24):1217-1220. PubMed ID: 33337270 [No Abstract] [Full Text] [Related]
33. Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing. Flotte TR; Gao G Hum Gene Ther; 2019 Dec; 30(12):1445-1446. PubMed ID: 31860398 [No Abstract] [Full Text] [Related]
35. Treatments that made headlines in 2018. Chakradhar S Nat Med; 2018 Dec; 24(12):1785-1787. PubMed ID: 30523326 [No Abstract] [Full Text] [Related]
36. Therapeutic and diagnostic relevance of Crispr technology. El Ouar I; Djekoun A Biomed Pharmacother; 2021 Jun; 138():111487. PubMed ID: 33774312 [TBL] [Abstract][Full Text] [Related]
37. Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease. Limanskiy V; Vyas A; Chaturvedi LS; Vyas D World J Gastroenterol; 2019 May; 25(18):2177-2187. PubMed ID: 31143069 [TBL] [Abstract][Full Text] [Related]
38. User-Friendly Technology the Key to Gene-Editing's Bloom: Market for Gene-Editing Tools Estimated at $608m and Growing as New Applications Are Found. Carlson B Hum Gene Ther Clin Dev; 2016 Dec; 27(4):137-139. PubMed ID: 27983891 [No Abstract] [Full Text] [Related]
39. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. Bhardwaj S; Kesari KK; Rachamalla M; Mani S; Ashraf GM; Jha SK; Kumar P; Ambasta RK; Dureja H; Devkota HP; Gupta G; Chellappan DK; Singh SK; Dua K; Ruokolainen J; Kamal MA; Ojha S; Jha NK J Adv Res; 2022 Sep; 40():207-221. PubMed ID: 36100328 [TBL] [Abstract][Full Text] [Related]
40. CRISPR/Cas9 technology as a potent molecular tool for gene therapy. Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]